



James C. Dickerson, MD MS

Clinical Assistant Professor, Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Stanford Womens Cancer Center**

900 Blake Wilbur

MC 5348

Palo Alto, CA 94304

Tel (650) 498-6004 **Fax** (650) 490-7237

Bio

BIO

Dr. Dickerson is a medical oncologist in the Division of Medical Oncology at Stanford University School of Medicine, specializing in the care of patients with breast cancer. In addition to seeing patients in the clinic, he researches how health policy, data science, and emerging technologies can improve cancer care delivery. His research group focuses on three core objectives: (1) developing financially sustainable cancer care programs, (2) analyzing large clinical and administrative datasets to identify gaps where policy can improve equity and outcomes, and (3) conducting clinical and implementation research to determine the most effective ways to deliver high-quality, evidence-based oncology care.

Across these objectives, Dr. Dickerson integrates traditional real-world data analytics with modern natural language processing approaches, including large language models, to study cancer care delivery. His group develops and applies LLM-based tools to improve the extraction, structuring, and interpretation of complex clinical information from electronic health records, to enhance clinical decision-making, care coordination, and health policy evaluation.

Dr. Dickerson received his undergraduate degree from Vanderbilt University and graduated magna cum laude from the University of Mississippi Medical Center. He completed his internship and residency in Internal Medicine at Stanford University, followed by fellowship training in Hematology and Oncology. During his fellowship, Dr. Dickerson earned a Master's degree in Health Policy and completed post-doctoral research in the Department of Health Policy.

CLINICAL FOCUS

- Breast Cancer
- Oncology

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology

HONORS AND AWARDS

- Conquer Cancer Merit Award, American Society for Clinical Oncology (2024)
- AOA, Alpha Omega Alpha (2018)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Global Health Faculty#Fellow, Center for Innovation in Global Health (CIGH) (2024 - present)
- Member, American Society of Clinical Oncology (ASCO) (2021 - present)

PROFESSIONAL EDUCATION

- Board Certification: Oncology, American Board of Internal Medicine (2024)
- Fellowship, Stanford University , Hematology and Oncology (2024)
- MS, Stanford University , Health Policy (2024)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2021)
- Residency, Stanford University , Internal Medicine (2021)
- MD, University of Mississippi Medical Center (2018)
- BA, Vanderbilt University (2014)

Publications

PUBLICATIONS

- **Improving human papillomavirus vaccine uptake in low- and middle-income countries: a narrative review of implementation and education strategies.** *BMC global and public health*
Kim, N., Ighodaro, E., Temple, M., Cleveland, A., Kc, D., Dickerson, J. C.
2026; 4 (1)
- **Guideline concordance in triple-negative breast cancer: What does it measure?** *Cancer*
Caswell-Jin, J. L., Dickerson, J. C., Kurian, A. W.
2026; 132 (7): e70381
- **Fully Automated Abstraction of Longitudinal Breast Oncology Records with Off-The-Shelf Large Language Models.** *medRxiv : the preprint server for health sciences*
Dickerson, J. C., McClure, M. B., Shaw, M., Reitsma, M. B., Dalal, N. H., Kurian, A. W., Caswell-Jin, J. L.
2026
- **Susan G. Komen's ShareForCures®: a patient-engaged, nationwide breast cancer research registry.** *Journal of the National Cancer Institute*
Jourquin, J., Dickerson, J. C., Marks, E. G., Epps, J., Sabelko, K., Kurian, A. W., Bondy, M. L.
2025
- **Reply to: Comment on Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Dickerson, J. C., Caswell-Jin, J. L., Riaz, F., Goldhaber-Fiebert, J. D., Alarid-Escudero, F.
2025: JCO2501879
- **Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Conforti, F., Merlo, F., Pala, L., Canzian, J., Tinterri, B., De Pas, T., Locatelli, M., Dickerson, J. C., Cortes, J., Slamon, D. J., Gelber, R., Bagnardi, V.
2025: JCO2501148
- **Physician Specialization and Receipt of Updated Breast Cancer Care in the United States: A SEER-Medicare Analysis.** *JCO oncology practice*
Caswell-Jin, J. L., Reitsma, M. B., Tang, H., Dickerson, J. C., Phillips, S., John, E. M., Kurian, A. W., Staiger, B., Goldhaber-Fiebert, J. D.
2025: OP2500462

- **The accuracy and efficiency of large language models for chart review in cancer genetics.**
Dickerson, J., Shaw, M., Satoyoshi, M., Rios-Ventura, S., Kingham, K., Kurian, A. W., Caswell-Jin, J.
LIPPINCOTT WILLIAMS & WILKINS.2025: e22603
- **Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Dickerson, J. C., Moen, M. T., Nielsen, P., Riaz, F., Tran, E., Caswell-Jin, J. L., Suen, W., Goldhaber-Fiebert, J. D., Alarid-Escudero, F.
2025: JCO2401960
- **Endocrine Therapy Interruption, Resumption, and Outcomes Associated With Pregnancy After Breast Cancer.** *JAMA oncology*
Ransohoff, J. D., Lewinsohn, R. M., Dickerson, J., Luo, I., Satoyoshi, M., Ritter, V., Chavez, R., Wheeler, A. J., Liang, S. Y., Kenkare, P., Gomez, S. L., Schapira, L., John, et al
2025
- **Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.** *JCO oncology practice*
Riaz, F., Vaughn, J. L., Zhu, H., Dickerson, J. C., Sayegh, H. E., Brongiel, S., Baldwin, E., Kier, M. W., Zaemes, J., Hearn, C., Abdelghany, O., Cohen, R. B., Parikh, et al
2025: OP2400788
- **Use of surgery for de novo metastatic breast cancer (mBC)**
Dickerson, J., Tang, H., Thompson, C., Gomez, S. L., Satoyoshi, M., Kurian, A. W., Caswell-Jin, J.
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Real-world duration of interruptions in imaging and endocrine therapy (ET) after pregnancy in early-stage estrogen receptor (ER) positive breast cancer (BC)**
Lewinsohn, R. M., Dickerson, J., Ransohoff, J., Luo, I., Satoyoshi, M., Ritter, V., Schapira, L., Kurian, A. W.
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan** *CURRENT PROBLEMS IN CANCER: CASE REPORTS*
Testa, S., Dickerson, J. C., Telli, M.
2023; 11
- **Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer**
Dickerson, J., Moen, M., Nielsen, P., Tran, E., Suen, W., Goldhaber-Fiebert, J. D., Alarid-Escudero, F.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Time From Symptom Development to Care Milestones at the Only Public Oncology Clinic in Belize**
Wong, W., Dickerson, J., Habet, M., Bernard, M., Kelly, L., Lattin, J., Garrity, P., Huang, F., Yacab, R.
AMER ASSOC CANCER RESEARCH.2023
- **The financial toxicity of chemotherapy in Belize**
Wong, W., Dickerson, J., Lattin, J., Ohanian, A., Habet, M., Bernard, M., Huang, F. W., Yacab, R.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Patient expectations and understanding of treatment intent in Belize.**
Dickerson, J., Wong, W., Ohanian, A., Habet, M., Bernard, M., Huang, F. W., Yacab, R.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Cancer Demographics and Time-to-Care in Belize.** *The oncologist*
Wong, W., Dickerson, J. C., Valtis, Y. K., Habet, M., Bernard, M., Kelly, L., Lattin, J., Garrity, P., Sood, R., Ohanian, A., Chege, M. W., Bhatt, A. S., Huang, et al
2023
- **Implementation and efficacy of a fellow-led, case-based noon lecture series.**
Dickerson, J., Myall, N., Roy, M., Johnson, T.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Breast cancer characteristics and time to chemotherapy initiation in Belize.**
Wong, W., Dickerson, J., Sood, R., Yacab, R., Valtis, Y., Lattin, J., Garrity, P., Bhatt, A., Huang, F. W.

LIPPINCOTT WILLIAMS & WILKINS.2022: E18643

- **Updated demographics at the only public oncology clinic in Belize.**
Wong, W., Dickerson, J., Sood, R., Valtis, Y., Yacab, R., Lattin, J., Garrity, P., Bhatt, A., Huang, F. W.
LIPPINCOTT WILLIAMS & WILKINS.2022: E18787
- **Patient-reported outcome measurement implementation in cancer survivors: a systematic review.** *Journal of cancer survivorship : research and practice*
Singhal, S., Dickerson, J., Glover, M. J., Roy, M., Chiu, M., Ellis-Caleo, T., Hui, G., Tamayo, C., Loecher, N., Wong, H. N., Heathcote, L. C., Schapira, L.
2022
- **Implementing Patient-Directed Cancer Education Materials Across Nigeria.** *JCO global oncology*
Dickerson, J. C., Ibeka, P., Inoyo, I., Oke, O. O., Adewuyi, S. A., Barry, D., Bello, A., Fasawe, O., Garrity, P., Habeebu, M., Huang, F. W., Mulema, V., Nwankwo, et al
2021; 7: 1610-1619
- **Financial Toxicity of Cancer Care: An Analysis of Financial Burden in Three Distinct Health Care Systems.** *JCO oncology practice*
Parikh, D. A., Ragavan, M., Dutta, R., Garnet Edwards, J., Dickerson, J., Maitra, D., Aggarwal, S., Lee, F., Patel, M. I.
2021: OP2000890
- **Healthcare delivery interventions to reduce cancer disparities worldwide.** *World journal of clinical oncology*
Dickerson, J. C., Ragavan, M. V., Parikh, D. A., Patel, M. I.
2020; 11 (9): 705–22
- **Health Disparities in Germline Genetic Testing for Cancer Susceptibility** *Current Breast Cancer Reports*
Parikh, D. A., Dickerson, J. C., Kurian, A. W.
2020
- **Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review** *JOURNAL OF PAIN AND SYMPTOM MANAGEMENT*
Hall, E. T., Singhal, S., Dickerson, J., Gabster, B., Wong, H., Aslakson, R. A., Schapira, L., Ast, K., Carroll, T., Dzeng, E., Harrison, K. L., Kaye, E. C., LeBlanc, et al
2019; 58 (1): 137-+
- **Variations in patient-reported outcome (PRO) collection and reporting in novel FDA approved anticancer therapies.**
Singhal, S., Hall, E., Gabster, B., Dickerson, J., Schapira, L.
AMER SOC CLINICAL ONCOLOGY.2019
- **"If you don't ask, you won't know": Do patient reported outcome (PRO) instruments capture the symptom experience of patients treated with immune checkpoint inhibitors (ICIs)?**
Gabster, B., Hall, E., Singhal, S., Dickerson, J., Schapira, L.
AMER SOC CLINICAL ONCOLOGY.2019
- **The impact of blinding on patient-reported outcomes (PROs) in randomized controlled trials of immune checkpoint inhibitors versus traditional chemotherapies.**
Dickerson, J., Hall, E., Singhal, S., Gabster, B., Schapira, L.
AMER SOC CLINICAL ONCOLOGY.2019
- **Patient reported outcomes for cancer patients receiving immunotherapy: opportunities for palliative care - A Systematic Review.** *Journal of pain and symptom management*
Hall, E. T., Singhal, S., Dickerson, J., Gabster, B., Wong, H., Aslakson, R. A., Schapira, L.
2019
- **Screening duplex ultrasonography in neurosurgery patients does not correlate with a reduction in pulmonary embolism rate or decreased mortality.** *Journal of neurosurgery*
Dickerson, J. C., Harriel, K. L., Dambrino, R. J., Taylor, L. I., Rimes, J. A., Chapman, R. W., Desrosiers, A. S., Tullis, J. E., Washington, C. W.
2019: 1–9